Clinical trial
A Phase 1, Dose Escalation, Double Blind, Placebo Controlled Clinical Trial With Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, MAM01, in Healthy, Malaria-Naive Adults
NCT05891236 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Dose Escalation, Double Blind, Placebo Controlled Clinical Trial With Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, MAM01, in Healthy, Malaria-Naive Adults
- Lead sponsor
- Gates Medical Research Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 14, 2023
- Completion date
- December 13, 2024
- Enrollment
- 63 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.